851 reports of this reaction
2.4% of all EXTENDED PHENYTOIN SODIUM reports
#5 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #5 most commonly reported adverse reaction for EXTENDED PHENYTOIN SODIUM, manufactured by Viatris Specialty LLC. There are 851 FDA adverse event reports linking EXTENDED PHENYTOIN SODIUM to DRUG HYPERSENSITIVITY. This represents approximately 2.4% of all 34,830 adverse event reports for this drug.
Patients taking EXTENDED PHENYTOIN SODIUM who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for EXTENDED PHENYTOIN SODIUM, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for EXTENDED PHENYTOIN SODIUM:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 851 FDA reports for EXTENDED PHENYTOIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 2.4% of all adverse event reports for EXTENDED PHENYTOIN SODIUM, making it a notable side effect.
If you experience drug hypersensitivity while taking EXTENDED PHENYTOIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.